TSPO and myeloid sarcoma: The aim of this proof of concept study was to identify the optimal plasma input tracer kinetic model for characterising in vivo [18F]DPA714 kinetics in patients with primary and secondary progressive MS and to evaluate whether the kinetic parameters estimated from this model can be used to quantify TSPO binding in this patient group.